Moderna’s Spikevax Receives TGA’s Provisional Approval to Treat COVID-19 in Patients Aged 12-17 Years

 Moderna’s Spikevax Receives TGA’s Provisional Approval to Treat COVID-19 in Patients Aged 12-17 Years

Shots:

  • TGA has provisionally approved the use of Moderna’s Spikevax (elasomeran) in individuals aged ≥12yrs. The decision follows the provisional approval granted by the TGA to Spikevax on Aug 09, 2021 for use in individuals aged ≥18yrs.
  • Provisional approval for this group follows the data supporting the efficacy & safety of the vaccine. The recommended dose and dose interval is like that of the adult population – 2 full doses given 28 days apart
  • The vaccine has received regulatory approval in this age group in several jurisdictions, including the UK, Canada, the EU, and Switzerland. TGA has secured 25M doses of Spikevax to diversify Australia’s vaccine portfolio as well as provide access to a booster or variant vaccine

Click here to­ read full press release/ article | Ref: TGA | Image: Stat News

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post